Drug Trial Radar · NCT04581473
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
Last checked: Nov 19, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Oct 23, 2020
Primary completion
Oct 18, 2024
Study completion Jun 30, 2038
Sponsor
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University Cancer Hospital & Institute; Fudan University
- First posted
- Oct 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer
Conditions
- Gastric Adenocarcinoma
- Pancreatic Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
CT041 autologous CAR T-cell injectionDrug
Up to 3 times CT041 autologous CAR T-cell injection infusion
Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)Drug
Physician's choice of any BSC listed above
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence of Treatment Related adverse events (AEs)Time frame: Up to 18 months
- Phase Ib: Identification of Maximum Tolerated Dose (MTD)Time frame: day1-day28
- Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physician's ChoiceTime frame: Up to 24 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Peking University Shenzhen Hospital
Shenzhen, Guangzhou, China
Harbin medical university Affiliated Cancer Hospital
Harbin, Heilongjia, China
Henan Tumor Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hanzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.